RE: CA 19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Preoperative Therapy

被引：0
|
作者：
Richard J. Bold
机构：
[1] University of California,Department of Surgery
[2] Davis Medical Center,undefined
来源：
Annals of Surgical Oncology | 2013年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2108 / 2110
页数：2
相关论文
共 50 条
  • [31] Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9
    Kowalchuk, Roman O.
    Lester, Scott C.
    Graham, Rondell P.
    Harmsen, William S.
    Zhang, Lizhi
    Halfdanarson, Thorvardur R.
    Smoot, Rory L.
    Gits, Hunter C.
    Ma, Wen Wee
    Owen, Dawn
    Mahipal, Amit
    Miller, Robert C.
    Wittich, Michelle A. Neben
    Cleary, Sean P.
    McWilliams, Robert R.
    Haddock, Michael G.
    Hallemeier, Christopher L.
    Truty, Mark J.
    Merrell, Kenneth W.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer
    Willett, CG
    Daly, WJ
    Warshaw, AL
    AMERICAN JOURNAL OF SURGERY, 1996, 172 (04): : 350 - 352
  • [33] CA 19-9: Not a magic marker for pancreatic cancer
    Daram, Sumanth R.
    SOUTHERN MEDICAL JOURNAL, 2006, 99 (03) : 205 - 205
  • [34] CA 19-9 and Lewis Antigens in Pancreatic Cancer
    Atkins, Carl D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2572 - 2573
  • [35] Is CA 19-9 useful in the management of pancreatic cancer?
    Balzano, Gianpaolo
    Di Carlo, Valerio
    LANCET ONCOLOGY, 2008, 9 (02): : 89 - 91
  • [36] Exploiting the relevance of CA 19-9 in pancreatic cancer
    Salleh, Syaza
    Thyagarajan, Anita
    Sahu, Ravi P.
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2020, 6
  • [37] Preoperative CA 19-9 does not Correlate with Loco-regional Tumor Cell Burden in Resectable Pancreatic Adenocarcinoma
    Bergquist, J.
    Puig, C. A.
    Shubert, C.
    Truty, M.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S175 - S176
  • [38] Prognostic impact of preoperative serum CA 19-9 level in pancreatic cancer: a pooled analysis
    Mattiucci, G. C.
    Morganti, A. G.
    Farioli, A.
    Frakulli, R.
    Cellini, F.
    Arcelli, A.
    Bertini, F.
    Forni, F.
    Fuccio, L.
    Farina, E.
    Ronchi, L.
    Guido, A.
    Macchia, G.
    Cammelli, S.
    Falconi, M.
    Valentini, V.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S78 - S78
  • [39] Tumor markers for pancreatic cancer: What happens when preoperative CA 19-9 is undetectable?
    Bouvet, M
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (07) : 637 - 638
  • [40] THE SEROLOGIC MARKER CA 19-9 AND PANCREATIC-CANCER
    NARDONE, DA
    ANNALS OF INTERNAL MEDICINE, 1989, 111 (02) : 184 - 185
12345